Phase III Clinical Study of Benvitimod Cream in the Treatment of Mild to Moderate Atopic Dermatitis
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, multicenter, placebo-controlled clinical Phase III study
to evaluate the safety and efficacy of Benvitimod cream, 1% twice daily for the treatment of
mild to moderate atopic dermatitis. Approximately 240 participants with mild to moderate
atopic dermatitis will be enrolled and randomly divided into two groups in a 2:1 ratio. They
will use either the Benvitimod cream or placebo at the skin with atopic dermatitis for 8
weeks.